Accro Bioscience and Fosun Pharma are preparing to advance AC-201 into a Phase II/III clinical trial in China for non-se...
Kelun-Biotech has reported positive interim Phase II results for SKB378/WIN378, an investigational ultra-long-acting mon...
Singapore is expanding subsidised access to Roche’s Columvi, or glofitamab, for eligible patients with relapsed or...
Shanghai-based DualityBio has entered a global collaboration and licensing agreement with Genentech to develop next-gene...
Alebund Pharmaceuticals has reported progress across its renal disease portfolio, including completion of enrolment in a...
Australian oncology biotechnology company Kazia Therapeutics has reported a 100% clinical benefit rate among the first s...
Artificial intelligence is increasingly being applied across early-stage drug discovery, but translating computational p...
Taiwan-based Lotus Pharmaceutical Co. has announced a strategic licensing and commercialisation agreement with Alvotech,...
As cell therapies advance towards greater clinical sophistication and commercial scale, the focus is shifting fr...
The US Food and Drug Administration has approved Moderna’s mFlusiva seasonal influenza vaccine for adults aged 50 ...
Shanghai Ark Biopharmaceutical, or ArkBio, has completed dosing across all healthy-volunteer cohorts in an Australian Ph...
Harbour BioMed and Kelun-Biotech have received approval from China’s National Medical Products Administration to b...
Antengene has received a $60 million upfront payment from UCB under a worldwide exclusive licensing agreement for ATG-20...
Asia's biopharmaceutical manufacturing sector is entering a new phase of growth, driven by expanding biologics pipelines...
Nektar Therapeutics has initiated the first two global registrational trials in its Phase 3 ZENITH AD programme for rezp...
Akeso has dosed the first patient in a Phase II clinical study evaluating AK146D1 in combination with ivonescimab for ad...
Halozyme Therapeutics has entered a global collaboration and licence agreement with Incyte to evaluate additional subcut...
Akeso has launched a Phase II clinical study in the United States evaluating a cadonilimab-based combination regimen for...
Innovent Biologics and Spero Therapeutics have entered into an exclusive licence agreement for IBI355, also known as SP0...
Harbour BioMed and Kelun-Biotech have received approval from China’s National Medical Products Administration for ...
Drug development is approaching a significant inflection point. Advances in induced pluripotent stem cells (iPSCs), orga...
US-based Organon, a global healthcare company with deep expertise in biosimilars, and Korea's Samsung Bioepis have annou...
Cell therapy is approaching a defining transition: from highly specialised science to a reproducible, scalable pharmaceu...
As BioSpectrum Asia reports on the ground from BIO Asia–Taiwan 2026, being held from July 15–19 in T...
Kelun-Biotech has reported positive Phase III results for sacituzumab tirumotecan, also known as sac-TMT or SKB264/MK-28...
